Back to the main directory
Company Analysis / Equity
- Riber - Key enabler of compound semiconductors by Edison Investment Research
- BIONTECH (NEUTRAL, TP USD206) | Benefits of mRNA vaccines still outweigh the risks in young adults by Bryan Garnier
- ONCODESIGN: R&D day feedback: On track to push multiple assets into clinical stage next year | CORPORATE | EUR15(+47%) by Bryan Garnier
- NOVO NORDISK: Semaglutide 2.0mg and tirzepatide both beat Ozempic: what’s now ? | BUY | DKK505(-2%) by Bryan Garnier
- VietNam Holding - The next five years and beyond by Edison Investment Research
- Record - Launch of new EM sustainable finance fund by Edison Investment Research
- OSE IMMUNO (CORPORATE, TP EUR17) | Manufacturing agreement to support development of COVID vaccine: by Bryan Garnier
- INVENTIVA (BUY, TP EUR26) | EASL data confirmed high efficacy of lanifibranor in NASH: by Bryan Garnier
- Greggs - Rate of recovery continues to surprise by Edison Investment Research
- MCPHY ENERGY: Potash leakage questions the reliability of McPhy’s electrolysers | CORPORATE | UNDER REVIEW by Bryan Garnier
- LMK GROUP: No hard-landing and better margin perspectives for 2021 | BUY | SEK154 VS. SEK150 (+114%) by Bryan Garnier
- RICHEMONT (NEUTRAL, TP CHF92) | Richemont expands on soft luxury with the Delvaux brand purchase: by Bryan Garnier
- BONE THERAPEUTICS (CORPORATE, TP EUR5.5) | EUR16m financing secured from the EIB: by Bryan Garnier
- Trackwise Designs - Strategic progress in challenging environment by Edison Investment Research
- AAC Clyde Space - SDaaS starting to lift off by Edison Investment Research
- Fidelity Asian Values - Termination of coverage by Edison Investment Research
- Fidelity European Trust - Termination of coverage by Edison Investment Research
- Orège - Termination of coverage by Edison Investment Research
- NICOX (BUY, TP EUR17.5) | Last patient completes NCX 4251 clinical trial, results expected in September: by Bryan Garnier
- SAFILO (BUY, TP EUR1.3) | Share capital increase up to EUR135m: by Bryan Garnier
- H & M: Stronger-than-expected Q2 results, current trading is normalizing | BUY | SEK235 VS. SEK225 (+16%) by Bryan Garnier
- H & M: H&M’s transformation strategy bodes well for future margins | BUY | SEK235(+16%) by Bryan Garnier
- INNATE PHARMA (BUY, TP EUR6.4) | No benefit with avdoralimab in covid-19-related pneumonia: by Bryan Garnier
- Palace Capital (PCA): Dividend recovery ahead of expectations by Hardman & Co
- Mercia Asset Management - FY21 a breakthrough year, with more to come by Edison Investment Research